This website is for HealthCare Professional audiences in Great Britain. Adverse event information can be found at the bottom of this page.

Welcome back
Aesthetics Associates

Evolus sells Nuceiva▼ (botulinum toxin type A) which is indicated for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines), when the severity of the above facial lines has an important psychological impact in adults below 65 years of age.1

Jayne chooses Nuceiva

"Having worked closely with patients, and witnessing firsthand the positive impact, I choose Nuceiva as my neuromodulator in clinic. It's precision, onset of effect and high patient satisfaction gives me peace of mind, as I know I can give my patients good results. As a nurse, I highly recommend you try Nuceiva through Aesthetics Associates"


- Jayne Beckett, Medical Director Aesthetics Associates

ARIELLE
at maximum frown

Arielle received a consultation with a healthcare professional prior to their Nuceiva treatment. Their HCP found them suitable for treatment. On October 3rd 2022, Arielle was treated with 20 units of Nuceiva across five injection sites: 2 injections in each corrugator muscle 1 injection in the procerus muscle Arielle was photographed at maximum frown before treatment (day 0) and on days 2, 30 and 120.

Individual results may vary

Nuceiva
at your own pace

  • Learn about its clinical profile
  • See safety and efficacy
  • Watch KOL's discuss how they introduced Nuceiva to their practice
  • Understand how Evolus works
Review Nuceiva data

Sign up to our
Evolus Service Platform

core benefits

  • Uncover detailed anatomy with our 5 glabella types course
  • Understand safety and efficacy of Nuceiva
  • Enroll for growth courses designed to help you ignite your practice
  • Schedule meetings with the Evolus MSL or MCM
Sign up to the ESP

References

1.) Nuceiva SmPC

ADVERSE EVENTS SHOULD BE REPORTED.

Reporting forms and information can be found at yellowcard.mhra.gov.uk/ or search MHRA yellow card in the Google Play or Apple App Store.

Adverse events should also be reported to Evolus International Ltd.

Please contact Evolus Europe Medical Information by [medicalinformation@evolus.com](mailto: medicalinformation@evolus.com) or calling 08000541302.